SCHEMBL2570752

SCHEMBL2570752

O=C(O)C(O)C(O)(C(=O)ON1C(=O)CCC1=O)N1C(=O)CCC1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16875690 1.00
SCHEMBL23781544 0.80 CPT2 (0.34)
SCHEMBL16875684 0.73 MGLL (0.32)
SCHEMBL230242 0.70
SCHEMBL57128 0.69 PARL (0.38)
SCHEMBL7924643 0.69 MGLL (0.32)
Bicarbonate SCHEMBL28277654 0.67 MGLL (0.36)
SCHEMBL23619542 0.67 MGLL (0.34)
SCHEMBL2570463 0.66 MGLL (0.33)
SCHEMBL6699078 0.66 MGLL (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114317439-A Method for culturing tumor organoid 北京基石生命科技有限公司 2022-04-12 CN disclosed
CN-114231491-A Method for preparing hydrogel personalized culture tumor organoid by using autologous pleural effusion and ascites of tumor patient 北京基石生命科技有限公司 2022-03-25 CN disclosed
EP-3939964-A1 COMBINATIONS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS Ardelyx, Inc. (US) 2022-01-19 EP disclosed
EP-3351248-B1 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS ARDELYX INC (US) 2021-06-09 EP disclosed
US-20150190389-A1 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDER ARDELYX, INC. (US) 2015-07-09 US disclosed
EP-2384318-A2 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS Ardelyx, Inc. (US) 2011-11-09 EP disclosed